M&T Bank Corp Tcr2 Therapeutics Inc. Transaction History

M&T Bank Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 07, 2022	SELL	$4.58 - $8.34 $84,038 - $153,030	-18,349 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$8.44 - $18.35 $55,543 - $120,761	6,581 Added 55.92%	18,349 $156,000
Q1 2021 May 06, 2021	SELL	$20.38 - $34.07 $41,615 - $69,570	-2,042 Reduced 14.79%	11,768 $260,000
Q2 2020 Jul 29, 2020	BUY	$6.51 - $16.85 $6,080 - $15,737	934 Added 7.25%	13,810 $212,000
Q1 2020 May 14, 2020	BUY	$6.01 - $16.01 $10,511 - $28,001	1,749 Added 15.72%	12,876 $100,000

Q4 2019 Feb 07, 2020	BUY	$12.17 - $17.88 $135,415 - $198,950	11,127 New	11,127 $159,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.